<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38523179</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-742X</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of thrombosis and thrombolysis</Title><ISOAbbreviation>J Thromb Thrombolysis</ISOAbbreviation></Journal><ArticleTitle>Persistent hypofibrinolysis in severe COVID-19 associated with elevated fibrinolysis inhibitors activity.</ArticleTitle><Pagination><StartPage>721</StartPage><EndPage>729</EndPage><MedlinePgn>721-729</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11239-024-02961-8</ELocationID><Abstract><AbstractText>Hypercoagulability and reduced fibrinolysis are well-established complications associated with COVID-19. However, the timelines for the onset and resolution of these complications remain unclear. The aim of this study was to evaluate, in a cohort of COVID-19 patients, changes in coagulation and fibrinolytic activity through ROTEM assay at different time points during the initial 30&#xa0;days following the onset of symptoms in both mild and severe cases. Blood samples were collected at five intervals after symptoms onset: 6-10&#xa0;days, 11-15&#xa0;days, 16-20&#xa0;days, 21-25&#xa0;days, and 26-30&#xa0;days. In addition, fibrinogen, plasminogen, PAI-1, and alpha 2-antiplasmin activities were determined. Out of 85 participants, 71% had mild COVID-19. Twenty uninfected individuals were evaluated as controls. ROTEM parameters showed a hypercoagulable state among mild COVID-19 patients beginning in the second week of symptoms onset, with a trend towards reversal after the third week of symptoms. In severe COVID-19 cases, hypercoagulability was observed since the first few days of symptoms, with a tendency towards reversal after the fourth week of symptoms onset. A hypofibrinolytic state was identified in severe COVID-19 patients from early stages and persisted even after 30&#xa0;days of symptoms. Elevated activity of PAI-1 and alpha 2-antiplasmin was also detected in severe COVID-19 patients. In conclusion, both mild and severe cases of COVID-19 exhibited transient hypercoagulability, reverted by the end of the first month. However, severe COVID-19 cases sustain hypofibrinolysis throughout the course of the disease, which is associated with elevated activity of fibrinolysis inhibitors. Persistent hypofibrinolysis could contribute to long COVID-19 manifestations.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Okazaki</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Sao Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina de Sao Paulo da USP, 255 - Cerqueira C&#xe9;sar, Sao Paulo, SP, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Barion</LastName><ForeName>B&#xe1;rbara Gomes</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>University of Sao Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina de Sao Paulo da USP, 255 - Cerqueira C&#xe9;sar, Sao Paulo, SP, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Rocha</LastName><ForeName>Tania Rubia Flores</ForeName><Initials>TRF</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina de Sao Paulo da USP, 255 - Cerqueira C&#xe9;sar, Sao Paulo, SP, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Giacomo</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina de Sao Paulo da USP, 255 - Cerqueira C&#xe9;sar, Sao Paulo, SP, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Yeh-Li</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina de Sao Paulo da USP, 255 - Cerqueira C&#xe9;sar, Sao Paulo, SP, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothschild</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina de Sao Paulo da USP, 255 - Cerqueira C&#xe9;sar, Sao Paulo, SP, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fatobene</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Sao Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho Moraes</LastName><ForeName>Bruna Del Guerra</ForeName><Initials>BDG</Initials><AffiliationInfo><Affiliation>University of Sao Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefanello</LastName><ForeName>Bianca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina de Sao Paulo da USP, 255 - Cerqueira C&#xe9;sar, Sao Paulo, SP, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villa&#xe7;a</LastName><ForeName>Paula Ribeiro</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina de Sao Paulo da USP, 255 - Cerqueira C&#xe9;sar, Sao Paulo, SP, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>Vanderson Geraldo</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina de Sao Paulo da USP, 255 - Cerqueira C&#xe9;sar, Sao Paulo, SP, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orsi</LastName><ForeName>Fernanda Andrade</ForeName><Initials>FA</Initials><Identifier Source="ORCID">0000-0002-7908-9073</Identifier><AffiliationInfo><Affiliation>Hospital das Cl&#xed;nicas da Faculdade de Medicina de Sao Paulo da USP, 255 - Cerqueira C&#xe9;sar, Sao Paulo, SP, 05403-000, Brazil. ferorsi@unicamp.br.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil. ferorsi@unicamp.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>88887.679326/2023-00</GrantID><Agency>Coordena&#xe7;&#xe3;o de Aperfei&#xe7;oamento de Pessoal de N&#xed;vel Superior</Agency><Country/></Grant><Grant><GrantID>038018/2021</GrantID><Agency>Minist&#xe9;rio da Sa&#xfa;de</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Thromb Thrombolysis</MedlineTA><NlmUniqueID>9502018</NlmUniqueID><ISSNLinking>0929-5305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017395">Plasminogen Activator Inhibitor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005342" MajorTopicYN="N">Fibrinolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017395" MajorTopicYN="N">Plasminogen Activator Inhibitor 1</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="Y">Antifibrinolytic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019851" MajorTopicYN="Y">Thrombophilia</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hypercoagulability</Keyword><Keyword MajorTopicYN="N">Hypofibrinolysis</Keyword><Keyword MajorTopicYN="N">Rotational thromboelastometry</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>25</Day><Hour>0</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38523179</ArticleId><ArticleId IdType="doi">10.1007/s11239-024-02961-8</ArticleId><ArticleId IdType="pii">10.1007/s11239-024-02961-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV (2022) A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 22(4):e102&#x2013;e107. https://doi.org/10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#xe1;&#x161;ek J et al (2022) COVID-19 associated coagulopathy: mechanisms and host-directed treatment. Am J Med Sci 363(6):465&#x2013;475. https://doi.org/10.1016/j.amjms.2021.10.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2021.10.012</ArticleId><ArticleId IdType="pubmed">34752741</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway EM et al (2022) Understanding COVID-19-associated coagulopathy. Nat Rev Immunol 22(10):639&#x2013;649. https://doi.org/10.1038/s41577-022-00762-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00762-9</ArticleId><ArticleId IdType="pubmed">35931818</ArticleId><ArticleId IdType="pmc">9362465</ArticleId></ArticleIdList></Reference><Reference><Citation>de Andrade Orsi FL, Campos Guerra JC (2020) Hipercoagulabilidade, eventos tromboemb&#xf3;licos e anticoagula&#xe7;&#xe3;o na COVID-19. Rev da Soc Cardiol do Estado S&#xe3;o Paulo 30(4):462&#x2013;471. https://doi.org/10.29381/0103-8559/20203004462-71</Citation><ArticleIdList><ArticleId IdType="doi">10.29381/0103-8559/20203004462-71</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahran AM, El-Badawy O, Ali WA, Mahran ZG, Mahran EEMO, Rayan A (2021) Circulating microparticles and activated platelets as novel prognostic biomarkers in COVID-19; relation to cancer. PLoS ONE 16(2):e0246806. https://doi.org/10.1371/journal.pone.0246806</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246806</ArticleId><ArticleId IdType="pubmed">33617530</ArticleId><ArticleId IdType="pmc">7899358</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting D, DiNardo JA (2014) TEG and ROTEM: technology and clinical applications. Am J Hematol 89(2):228&#x2013;232. https://doi.org/10.1002/ajh.23599</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.23599</ArticleId><ArticleId IdType="pubmed">24123050</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;rlinger K et al (2021) The role of rotational thromboelastometry during the COVID-19 pandemic: a narrative review. Korean J Anesthesiol 74(2):91&#x2013;102. https://doi.org/10.4097/kja.21006</Citation><ArticleIdList><ArticleId IdType="doi">10.4097/kja.21006</ArticleId><ArticleId IdType="pubmed">33440114</ArticleId><ArticleId IdType="pmc">8024216</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;nenli MG, Komesli Z, &#x130;ncir S, Yal&#xe7;&#x131;n &#xd6;, Akay OM (2021) Rotational thromboelastometry reveals distinct coagulation profiles for patients with covid-19 depending on disease severity. Clin Appl Thromb 27:107602962110276. https://doi.org/10.1177/10760296211027653</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10760296211027653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzeffi MA, Chow JH, Tanaka K (2021) COVID-19 associated hypercoagulability: manifestations, mechanisms, and management. Shock 55(4):465&#x2013;471. https://doi.org/10.1097/SHK.0000000000001660</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001660</ArticleId><ArticleId IdType="pubmed">32890309</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada H, Shiraki K, Shimpo H, Shimaoka M, Iba T, Suzuki-Inoue K (2023) Thrombotic mechanism involving platelet activation, hypercoagulability and hypofibrinolysis in coronavirus disease 2019. Int J Mol Sci 24(9):7975. https://doi.org/10.3390/ijms24097975</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24097975</ArticleId><ArticleId IdType="pubmed">37175680</ArticleId><ArticleId IdType="pmc">10178520</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulshof A-M et al (2021) Serial EXTEM, FIBTEM, and tPA rotational thromboelastometry observations in the maastricht intensive care COVID cohort&#x2014;persistence of hypercoagulability and hypofibrinolysis despite anticoagulation. Front. Cardiovasc Med 8:654174. https://doi.org/10.3389/fcvm.2021.654174</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.654174</ArticleId><ArticleId IdType="pubmed">33981736</ArticleId><ArticleId IdType="pmc">8107372</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blydenstein SA et al (2021) Prevalence and trajectory of COVID-19-associated hypercoagulability using serial thromboelastography in a south african population. Crit Care Res Pract 2021:1&#x2013;9. https://doi.org/10.1155/2021/3935098</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/3935098</ArticleId></ArticleIdList></Reference><Reference><Citation>Toomer KH et al (2023) SARS-CoV-2 infection results in upregulation of plasminogen activator inhibitor-1 and neuroserpin in the lungs, and an increase in fibrinolysis inhibitors associated with disease severity. ejHaem 4(2):324&#x2013;338. https://doi.org/10.1002/jha2.654</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jha2.654</ArticleId><ArticleId IdType="pubmed">37206290</ArticleId><ArticleId IdType="pmc">10188457</ArticleId></ArticleIdList></Reference><Reference><Citation>Polok K et al (2023) The temporal changes of hemostatic activity in hospitalized patients with COVID-19: a prospective observational study. Polish Arch Intern Med. https://doi.org/10.20452/pamw.16446</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.16446</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon U (2023) Native whole blood (TRUE-NATEM) and recalcified citrated blood (NATEM) reference value validation with ROTEM delta. Semin Cardiothorac Vasc Anesth 27(3):108925322311515. https://doi.org/10.1177/10892532231151528</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10892532231151528</ArticleId></ArticleIdList></Reference><Reference><Citation>Meesters MI, Koch A, Kuiper G, Zacharowski K, Boer C (2015) Instability of the non-activated rotational thromboelastometry assay (NATEM) in citrate stored blood. Thromb Res 136(2):481&#x2013;483. https://doi.org/10.1016/j.thromres.2015.05.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2015.05.026</ArticleId><ArticleId IdType="pubmed">26044665</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;chl H, Solomon C, Laux V, Heitmeier S, Bahrami S, Redl H (2012) Similarities in thromboelastometric (ROTEM&#xae;) findings between humans and baboons. Thromb Res 130(3):e107&#x2013;e112. https://doi.org/10.1016/j.thromres.2012.03.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2012.03.</ArticleId><ArticleId IdType="pubmed">22482831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadzia HK et al (2021) Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. Am J Obstet Gynecol 225(1):85.e1-85.e11. https://doi.org/10.1016/j.ajog.2020.11.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2020.11.035</ArticleId><ArticleId IdType="pubmed">33248975</ArticleId></ArticleIdList></Reference><Reference><Citation>Duca S-T, Costache A-D, Miftode R-&#x218;, Mitu O, Petri&#x219; A-O, Costache I-I (2022) Hypercoagulability in COVID-19: from an unknown beginning to future therapies. Med Pharm Rep 95(3):236&#x2013;242. https://doi.org/10.15386/mpr-2195</Citation><ArticleIdList><ArticleId IdType="doi">10.15386/mpr-2195</ArticleId><ArticleId IdType="pubmed">36060499</ArticleId><ArticleId IdType="pmc">9387574</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigada M et al (2020) Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 18(7):1738&#x2013;1742. https://doi.org/10.1111/jth.14850</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14850</ArticleId><ArticleId IdType="pubmed">32302438</ArticleId><ArticleId IdType="pmc">9906150</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844&#x2013;847. https://doi.org/10.1111/jth.14768</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14768</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId><ArticleId IdType="pmc">7166509</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708&#x2013;1720. https://doi.org/10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497&#x2013;506. https://doi.org/10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId><ArticleId IdType="pmc">7159299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali N (2020) Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol 92(11):2409&#x2013;2411. https://doi.org/10.1002/jmv.26097</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26097</ArticleId><ArticleId IdType="pubmed">32516845</ArticleId><ArticleId IdType="pmc">7301027</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrati C et al (2021) Elevated P-selectin in severe Covid-19: considerations for therapeutic options. Mediterr J Hematol Infect Dis 13(1):e2021016. https://doi.org/10.4084/mjhid.2021.016</Citation><ArticleIdList><ArticleId IdType="doi">10.4084/mjhid.2021.016</ArticleId><ArticleId IdType="pubmed">33747397</ArticleId><ArticleId IdType="pmc">7938922</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal M, Dass J, Mahapatra M (2020) Hemostatic abnormalities in COVID-19: an update. Indian J Hematol Blood Transfus 36(4):616&#x2013;626. https://doi.org/10.1007/s12288-020-01328-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12288-020-01328-2</ArticleId><ArticleId IdType="pubmed">32837053</ArticleId><ArticleId IdType="pmc">7418883</ArticleId></ArticleIdList></Reference><Reference><Citation>Corr&#xea;a TD et al (2020) Coagulation profile of COVID-19 patients admitted to the ICU: an exploratory study. PLoS ONE 15(12):e0243604. https://doi.org/10.1371/journal.pone.0243604</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243604</ArticleId><ArticleId IdType="pubmed">33320874</ArticleId><ArticleId IdType="pmc">7737963</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvet L et al (2022) Hypercoagulability in critically ill patients with COVID 19, an observational prospective study. PLoS ONE 17(11):e0277544. https://doi.org/10.1371/journal.pone.0277544</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0277544</ArticleId><ArticleId IdType="pubmed">36417476</ArticleId><ArticleId IdType="pmc">9683576</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba&#xf1;ez C et al (2021) High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there? J Thromb Thrombolysis 51(2):308&#x2013;312. https://doi.org/10.1007/s11239-020-02226-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02226-0</ArticleId><ArticleId IdType="pubmed">32671609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrovic M et al (2021) Rotational thromboelastometry (ROTEM) profiling of COVID-19 patients. Platelets 32(5):690&#x2013;696. https://doi.org/10.1080/09537104.2021.1881949</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537104.2021.1881949</ArticleId><ArticleId IdType="pubmed">33561381</ArticleId></ArticleIdList></Reference><Reference><Citation>van Veenendaal N, Scheeren TWL, Meijer K, van der Voort PHJ (2020) Rotational thromboelastometry to assess hypercoagulability in COVID-19 patients. Thromb Res 196:379&#x2013;381. https://doi.org/10.1016/j.thromres.2020.08.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.08.046</ArticleId><ArticleId IdType="pubmed">32980621</ArticleId><ArticleId IdType="pmc">7462575</ArticleId></ArticleIdList></Reference><Reference><Citation>Boss K, Kribben A, Tyczynski B (2021) Pathological findings in rotation thromboelastometry associated with thromboembolic events in COVID-19 patients. Thromb J 19(1):10. https://doi.org/10.1186/s12959-021-00263-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-021-00263-0</ArticleId><ArticleId IdType="pubmed">33573670</ArticleId><ArticleId IdType="pmc">7877314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruse JM et al (2020) Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. Crit Care 24(1):676. https://doi.org/10.1186/s13054-020-03401-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03401-8</ArticleId><ArticleId IdType="pubmed">33287877</ArticleId><ArticleId IdType="pmc">7719734</ArticleId></ArticleIdList></Reference><Reference><Citation>Elaa A et al (2022) Assessment of coagulation profiles by rotational thromboelastometry in COVID 19 patients. Clin Lab 68(8):2022. https://doi.org/10.7754/Clin.Lab.2021.211026</Citation><ArticleIdList><ArticleId IdType="doi">10.7754/Clin.Lab.2021.211026</ArticleId></ArticleIdList></Reference><Reference><Citation>Gando S, Levi M, Toh C-H (2016) Disseminated intravascular coagulation. Nat Rev Dis Prim 2(1):16037. https://doi.org/10.1038/nrdp.2016.37</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.37</ArticleId><ArticleId IdType="pubmed">27250996</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Levy JH (2020) Sepsis-induced coagulopathy and disseminated intravascular coagulation. Anesthesiology 132(5):1238&#x2013;1245. https://doi.org/10.1097/ALN.0000000000003122</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000003122</ArticleId><ArticleId IdType="pubmed">32044801</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Levy JH, Thachil J, Wada H, Levi M (2019) The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. Thromb Res 179:11&#x2013;14. https://doi.org/10.1016/j.thromres.2019.04.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2019.04.030</ArticleId><ArticleId IdType="pubmed">31059996</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsantes AG et al (2023) Sepsis-induced coagulopathy: an update on pathophysiology, biomarkers, and current guidelines. Life 13(2):350. https://doi.org/10.3390/life13020350</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13020350</ArticleId><ArticleId IdType="pubmed">36836706</ArticleId><ArticleId IdType="pmc">9961497</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungurlu S, Kuppy J, Balk RA (2020) Role of antithrombin III and tissue factor pathway in the pathogenesis of sepsis. Crit Care Clin 36(2):255&#x2013;265. https://doi.org/10.1016/j.ccc.2019.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccc.2019.12.002</ArticleId><ArticleId IdType="pubmed">32172812</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M, van der Poll T (2017) Coagulation and sepsis. Thromb Res 149:38&#x2013;44. https://doi.org/10.1016/j.thromres.2016.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2016.11.007</ArticleId><ArticleId IdType="pubmed">27886531</ArticleId></ArticleIdList></Reference><Reference><Citation>Degen JL, Bugge TH, Goguen JD (2007) Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 5:24&#x2013;31. https://doi.org/10.1111/j.1538-7836.2007.02519.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2007.02519.x</ArticleId><ArticleId IdType="pubmed">17635705</ArticleId></ArticleIdList></Reference><Reference><Citation>Creel-Bulos C et al (2021) Fibrinolysis shutdown and thrombosis in a COVID-19 ICU. Shock 55(3):316&#x2013;320. https://doi.org/10.1097/SHK.0000000000001635</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001635</ArticleId><ArticleId IdType="pubmed">32769822</ArticleId><ArticleId IdType="pmc">8858425</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright FL et al (2020) Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg 231(2):193-203e1. https://doi.org/10.1016/j.jamcollsurg.2020.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2020.05.007</ArticleId><ArticleId IdType="pubmed">32422349</ArticleId><ArticleId IdType="pmc">7227511</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P (2021) NICE guideline on long COVID. Lancet Respir Med 9(2):129. https://doi.org/10.1016/S2213-2600(21)00031-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00031-X</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId><ArticleId IdType="pmc">7832375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambaglio C et al (2022) Role of hemostatic biomarkers for the identification of patients with LONG-COVID19 syndrome: results from the &#x2018;Accordi&#x2019; study. Blood 140(Supplement 1):2652&#x2013;2653. https://doi.org/10.1182/blood-2022-162206</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2022-162206</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E et al (2021) Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol 20(1):172. https://doi.org/10.1186/s12933-021-01359-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId><ArticleId IdType="pmc">8381139</ArticleId></ArticleIdList></Reference><Reference><Citation>Baycan OF (2022) Plasminogen activator inhibitor-1 levels as an indicator of severity and mortality for COVID-19. North Clin Istanbul. https://doi.org/10.14744/nci.2022.09076</Citation><ArticleIdList><ArticleId IdType="doi">10.14744/nci.2022.09076</ArticleId></ArticleIdList></Reference><Reference><Citation>Nougier C et al (2020) Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost 18(9):2215&#x2013;2219. https://doi.org/10.1111/jth.15016</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15016</ArticleId><ArticleId IdType="pubmed">32668058</ArticleId><ArticleId IdType="pmc">7405476</ArticleId></ArticleIdList></Reference><Reference><Citation>Whyte CS et al (2022) The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. J Thromb Haemost 20(10):2394&#x2013;2406. https://doi.org/10.1111/jth.15806</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15806</ArticleId><ArticleId IdType="pubmed">35780481</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S et al (2020) IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci 117(36):22351&#x2013;22356. https://doi.org/10.1073/pnas.2010229117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2010229117</ArticleId><ArticleId IdType="pubmed">32826331</ArticleId><ArticleId IdType="pmc">7486751</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y et al (2021) Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep 11(1):1580. https://doi.org/10.1038/s41598-020-80010-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80010-z</ArticleId><ArticleId IdType="pubmed">33452298</ArticleId><ArticleId IdType="pmc">7810990</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry BM, Benoit SW, Hoehn J, Lippi G, Favaloro EJ, Benoit JL (2020) Circulating plasminogen concentration at admission in patients with coronavirus disease 2019 (COVID-19). Semin Thromb Hemost 46(07):859&#x2013;862. https://doi.org/10.1055/s-0040-1715454</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1715454</ArticleId><ArticleId IdType="pubmed">32882718</ArticleId><ArticleId IdType="pmc">7645831</ArticleId></ArticleIdList></Reference><Reference><Citation>Gando S, Kameue T, Nanzaki S, Nakanishi Y (1996) Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 75(02):224&#x2013;228. https://doi.org/10.1055/s-0038-1650248</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1650248</ArticleId><ArticleId IdType="pubmed">8815564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA (2006) TAFI and PAI-1 levels in human sepsis. Thromb Res 118(2):205&#x2013;212. https://doi.org/10.1016/j.thromres.2005.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2005.06.007</ArticleId><ArticleId IdType="pubmed">16009400</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>